Kiora Pharmaceuticals presents plans for global Phase 3 trial of KIO-401 in retinal artery occlusion
KPRX•Kiora Pharmaceuticals plans a global Phase 3 trial of KIO-401, enrolling approximately 144 patients at up to 50 sites. Japan Phase 3 results showed p=0.0949 overall and p=0.0195 among patients with baseline vision worse than 20/400.
1. KIO-401 development plans
Kiora Pharmaceuticals added KIO-401, a Phase 3-ready oral calpain inhibitor for central retinal artery occlusion, securing rights outside Asia from Senju Pharmaceutical. The planned global Phase 3 trial will enroll approximately 144 patients across up to 50 sites.
2. Other trial programs
Japan Phase 3 visual acuity results showed p=0.0949 overall versus p=0.0195 in patients with baseline vision worse than 20/400. Planned NAION development includes a Phase 2b trial enrolling approximately 272 patients, with label expansion targeted for 2033. KIO-301 remains in an actively enrolling Phase 2 trial for advanced retinitis pigmentosa.
